Roth Capital Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Strong-Buy

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by stock analysts at Roth Capital to a “strong-buy” rating in a research report issued on Monday, Zacks reports.

A number of other research analysts also recently weighed in on the stock. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. JPMorgan Chase & Co. initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price objective for the company. Finally, Truist Financial raised their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $128.54.

Dianthus Therapeutics Stock Up 0.2%

Shares of DNTH opened at $79.52 on Monday. Dianthus Therapeutics has a twelve month low of $32.28 and a twelve month high of $117.88. The company has a 50 day moving average of $94.59 and a 200-day moving average of $83.94.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, sell-side analysts predict that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $425,640. This represents a 85.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Anne McGeorge sold 7,750 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the sale, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 242,429 shares of company stock worth $26,118,913 in the last quarter. 3.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNTH. Sterling Capital Management LLC grew its holdings in Dianthus Therapeutics by 840.4% during the third quarter. Sterling Capital Management LLC now owns 1,561 shares of the company’s stock worth $137,000 after purchasing an additional 1,395 shares during the period. QP Wealth Management LLC bought a new stake in Dianthus Therapeutics in the third quarter valued at approximately $316,000. Nisa Investment Advisors LLC raised its stake in Dianthus Therapeutics by 75.0% in the third quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after buying an additional 453 shares during the period. Eagle Bay Advisors LLC bought a new stake in Dianthus Therapeutics in the third quarter valued at approximately $218,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Dianthus Therapeutics by 160.9% in the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after buying an additional 451,597 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.